부산대학교 도서관

Recently, concerns were raised of high rates of HCC recurrence in patients treated with direct-acting antivirals ( DAA) for hepatitis C infection. We investigated the HCC occurrence and recurrence rates within 6 months after treatment with DAA with or without pegylated interferon ( PEG- IFN) in real life. This is a retrospective, multicenter cohort trial, executed in 15 hospitals distributed across Belgium. Populations were matched based on fibrosis score (Metavir F3-F4). Patients with a Child-Pugh score ≥ B were excluded. In total, 567 patients were included, of whom 77 were treated with PEG- IFN+ DAA between 2008 and 2013 and 490 with DAA without PEG- IFN between 2013 and 2015. Patients treated with PEG- IFN+ DAA (53±9y) were younger than patients treated with DAA without PEG- IFN (59±12y) ( P=.001). 47% of patients treated with PEG- IFN+ DAA were in the F4 stage vs 67% of patients treated with DAA without PEG- IFN ( P=.001). Screening was inadequate in 20% of both patient groups ( P=.664). The early occurrence rate of HCC was 1.7% and 1.1% in patients treated with DAA with and without PEG- IFN, respectively ( P=.540). The early recurrence rate was 0% in patients treated with PEG- IFN+ DAA and 15.0% in patients treated with DAA without PEG- IFN ( P=.857). There is no difference in early occurrence of new HCC between patients treated with DAA with and without PEG- IFN. We did observe a high early recurrence rate of HCC in patients treated with DAA without PEG- IFN. However, these patients were at baseline more at risk for HCC. Finally, in 20%, screening for HCC was inadequate. [ABSTRACT FROM AUTHOR]